Moreover, oncogenic KRAS reduces pancreatic FGF21 expression, a metabolic regulator that prevents obesity, partially through downregulating peroxisome proliferator-activated receptor (PPAR)G (12). The gene discussed is KRAS; the disease is obesity disorder.